82840-40-2

Basic information

• Product Name: 3,5 - dibroMo - 6 - oxo - 6H - anthraisoxazole
• Synonyms: 3,5 - dibroMo - 6 - oxo - 6H - anthraisoxazole;6H-Anthra[1,9-cd]isoxazol-6-one, 3,5-dibromo-;3,5-dibromo-6H-anthra[1,9-cd]isoxazol-6-one;EOS-60714
• CAS NO: 82840-40-2
• Molecular Formula: C₁₄H₅Br₂NO₂
• Molecular Weight: 379
• EINECS: -0
• Mol File: 82840-40-2.mol
• Article Data: 12

Chemical Properties

• Melting Point: 247-248 °C(Solv: acetic acid (64-19-7))
• Boiling Point: 551.7±50.0 °C(Predicted)
• Appearance: /
• Density: 2.023±0.06 g/cm3(Predicted)
• PKA: -11.21±0.20(Predicted)
• CAS DataBase Reference: 3,5 - dibroMo - 6 - oxo - 6H - anthraisoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5 - dibroMo - 6 - oxo - 6H - anthraisoxazole(82840-40-2)
• EPA Substance Registry System: 3,5 - dibroMo - 6 - oxo - 6H - anthraisoxazole(82840-40-2)

Safety Data

• Hazardous Substances Data: 82840-40-2(Hazardous Substances Data)

Upstream product

• 81-49-2 1-amino-2, 4-dibromoanthraquinone 
• 82-45-1 1-amino-9,10-anthracenedione 
• 481-39-0 5-hydroxynaphtho-1,4-quinone 
• 129-43-1 1-hydroxyanthraquinone 
• 130-15-4 [1,4]naphthoquinone 

Downstream Products

• 92629-28-2 3-Bromo-5-aziridinoanthra<1,9-cd>-6-isoxazolone 
• 106981-07-1 3-Bromo-5-(3,5-dimethyl-phenylamino)-anthra[1,9-cd]isoxazol-6-one 
• 109776-50-3 3-Bromo-5-(3,4-dimethyl-phenylamino)-anthra[1,9-cd]isoxazol-6-one 
• 106960-81-0 6-H-6-oxo-3-bromo-5-benzyloxyanthra<1,9-cd>isoxazole 
• 106960-83-2 3-Bromo-5-p-tolyloxy-anthra[1,9-cd]isoxazol-6-one 
• 81-49-2 1-amino-2, 4-dibromoanthraquinone 
• 111334-91-9 3-bromo-5-(4-ethoxyphenyl)-6-oxo-6H-anthra<1,9-cd>isoxazole 
• 105551-35-7 3,5-di-(4-methoxyphenoxy)anthra<1,9-cd>-6-isoxazolone 
• 139488-56-5 2,4-Dibromo-1-cyclohexylamino-anthraquinone 

Relevant articles and documents

SMALL MOLECULE MODULATORS OF GSK-3 ACTIVITY

Compounds usable as substrate-competitive inhibitors of GSK-3, and uses thereof in modulating (e.g., inhibiting) GSK-3 activity and in treating biological conditions associated with GSK-3, are provided. The compounds can be collectively represented by Formula I, II or III, as described in the specification.

BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS

The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, FcyRI, FcRN, Transferrin or Macrophage Scavenger receptor. Pharmaceutical compositions based upon these bifunctional small molecules represent an additional aspect of the present invention. These compounds and/or compositions may be used to treat disease states and conditions by removing circulating proteins through degradation in the hepatocytes or macrophages of a patient or subject in need of therapy. Methods of treating disease states and/or conditions in which circulating proteins are associated with the disease state and/or condition are also described herein.

SMALL MOLECULE BASED ANTIBODY-RECRUITING COMPOUNDS FOR CANCER TREATMENT

The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.